Inflammatory breast cancer (IBC) is an extremely lethal cancer that rapidly metastasizes. Although the molecular attributes of IBC have been described, little is known about the underlying metabolic features of the disease. Using a variety of metabolic assays, including 13C tracer experiments, we found that SUM149 cells, the primary in vitro model of IBC, exhibit metabolic abnormalities that distinguish them from other breast cancer cells, including elevated levels of N-acetylaspartate, a metabolite primarily associated with neuronal disorders and gliomas. Here we provide the first evidence of N-acetylaspartate in breast cancer. We also report that the oncogene RhoC, a driver of metastatic potential, modulates glutamine and N-acetylaspartate metabolism in IBC cells in vitro, revealing a novel role for RhoC as a regulator of tumor cell metabolism that extends beyond its well known role in cytoskeletal rearrangement.
RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells*
Michelle L. Wynn,J. Yates,Charles R. Evans,Lauren D. Van Wassenhove,Zhi-fen Wu,Sydney Bridges,Liwei Bao,Chelsea L. Fournier,S. Ashrafzadeh,M. Merrins,L. Satin,S. Schnell,C. Burant,S. Merajver
Published 2016 in Journal of Biological Chemistry
ABSTRACT
PUBLICATION RECORD
- Publication year
2016
- Venue
Journal of Biological Chemistry
- Publication date
2016-04-25
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-53 of 53 references · Page 1 of 1
CITED BY
Showing 1-33 of 33 citing papers · Page 1 of 1